Drug Type Small molecule drug |
Synonyms N-(2-(4-Fluorophenyl)-5,7-dimethyl-1,2,3,4-tetrahydro isoquinolin-6-yl)-2-(1-methylcyclopropyl) acetamide, CB-003 |
Target |
Mechanism Kv7.2 stimulants(Voltage-gated potassium channel subunit Kv7.2 stimulants), Kv7.3 stimulants(Potassium voltage-gated channel subfamily KQT member 3 stimulants) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Start Date17 Aug 2023 |
Sponsor / Collaborator [+3] |
Start Date21 Jun 2023 |
Sponsor / Collaborator [+3] |
Start Date29 Nov 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 1 | US | 11 May 2022 | |
Amyotrophic Lateral Sclerosis | Preclinical | CN | 24 Feb 2022 | |
Depressive Disorder | Preclinical | CN | 24 Feb 2022 | |
Neuralgia | Preclinical | CN | 24 Feb 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |